Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain.
about
A possible pharmacological explanation for quinacrine failure to treat prion diseases: pharmacokinetic investigations in a ovine model of scrapieThe biological significance of brain barrier mechanisms: help or hindrance in drug delivery to the central nervous system?Challenges of using in vitro data for modeling P-glycoprotein efflux in the blood-brain barrier.Effect of blood brain barrier permeability in recurrent high grade gliomas on the intratumoral pharmacokinetics of methotrexate: a microdialysis studyTissue concentration of systemically administered antineoplastic agents in human brain tumors.Translational pharmacokinetics: challenges of an emerging approach to drug development in stroke.Concentration-effect relationships for the drug of abuse gamma-hydroxybutyric acidHow to measure drug transport across the blood-brain barrierPenetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections.Translational PK-PD modelling of molecular target modulation for the AMPA receptor positive allosteric modulator Org 26576.Therapeutic concentrations of glucagon-like peptide-1 in cerebrospinal fluid following cell-based delivery into the cerebral ventricles of catsMass spectrometry imaging reveals heterogeneous efavirenz distribution within putative HIV reservoirsEffect of protein binding on unbound atazanavir and darunavir cerebrospinal fluid concentrations.Mechanistic basis of adverse drug reactions: the perils of inappropriate dose schedules.Kinetics of drug action in disease states: towards physiology-based pharmacodynamic (PBPD) models.Toward the prediction of CNS drug-effect profiles in physiological and pathological conditions using microdialysis and mechanism-based pharmacokinetic-pharmacodynamic modeling.The mastermind approach to CNS drug therapy: translational prediction of human brain distribution, target site kinetics, and therapeutic effects.CNS pharmacokinetics of antifungal agents.On the rate and extent of drug delivery to the brain.Physiologically based pharmacokinetic modelling of drug penetration across the blood-brain barrier--towards a mechanistic IVIVE-based approachDelivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain.Importance of Peptide transporter 2 on the cerebrospinal fluid efflux kinetics of glycylsarcosine characterized by nonlinear mixed effects modeling.Drug interactions at the blood-brain barrier: fact or fantasy?Penetration of colistin into cerebrospinal fluidIntracerebroventricular administration of drugs.Prediction of antiepileptic drug efficacy: the use of intracerebral microdialysis to monitor biophase concentrations.Assessing brain free fraction in early drug discovery.Microdialysis for assessing intratumoral drug disposition in brain cancers: a tool for rational drug development.Full efficacy with no CNS side-effects: unachievable panacea or reality? DMPK considerations in design of drugs with limited brain penetration.Strategies to minimize CNS toxicity: in vitro high-throughput assays and computational modeling.The proteomic toolbox for studying cerebrospinal fluid.Physiologically based pharmacokinetic modeling to investigate regional brain distribution kinetics in rats.Utility of CSF in translational neuroscience.In vitro, in vivo and in silico models of drug distribution into the brain.Role of microdialysis in pharmacokinetics and pharmacodynamics: current status and future directions.Overview of experimental models of the blood-brain barrier in CNS drug discovery.The nasal approach to delivering treatment for brain diseases: an anatomic, physiologic, and delivery technology overview.Blood-brain barrier models: in vitro to in vivo translation in preclinical development of CNS-targeting biotherapeutics.Translational aspects of blood-brain barrier transport and central nervous system effects of drugs: from discovery to patients.Reliability of In Vitro and In Vivo Methods for Predicting the Effect of P-Glycoprotein on the Delivery of Antidepressants to the Brain.
P2860
Q24670616-BF82264A-345A-49D4-8AAC-3B320C96E4C2Q26753140-89A68548-98CA-49C6-A8D2-27540333D643Q30651426-CFC9A400-66DD-42FE-9FE3-9A489AB9FDDCQ33642314-D2E6690D-C66D-498A-B5BD-0462212C7893Q33844823-3DCF6E53-7FAC-42B3-836B-D581FE34E089Q33882182-382A5D32-EDDC-473C-B2FB-34921E93E9BCQ33890946-6A5F6921-18E4-4936-AD0B-E6A27D769A73Q33985116-E78445E6-9E9B-4A68-ACB8-1634E3D04565Q34142328-1BA04217-A491-48FF-AB89-6ADAE46E4C03Q34190402-276D5476-40DD-4551-BE85-550D804B2627Q35044628-2B71D060-21F1-4D30-B084-404DA31D50EAQ35385971-DBEB12B2-890D-4392-8C74-5E3A2FEA5C7AQ35404442-01726CD4-FC98-4F78-ACFD-0DF5362B1C2DQ36040772-6F732F6B-52B6-4CF6-AC6E-2F5DB8A296E7Q36090728-2FF2D3C0-F54C-409E-A814-DBF6AD3BBE95Q36341660-F8D42E37-4ACC-4EAA-A4DD-1BE905F7634BQ36697929-A3D88DC0-219B-4630-AD13-9D1303748A9BQ36909333-C7DCA95E-8FF1-4A4B-8478-3B0C1623F4F2Q37023904-93DD45D9-E65F-4E08-A6FA-A1E8BD54AB15Q37207750-49B5B06A-075F-434F-B947-EBF6E5D718BEQ37308322-BF12875D-A6BF-4105-8CFE-79F4562381A9Q37327301-19D126C3-D4B0-4CE8-8FAC-9814F8140642Q37362486-67AFE4E0-E6F2-472E-986F-96B1590EB9F5Q37409872-EDB44E50-C8B9-4AF1-B6FC-CE9BB0D6AAFDQ37532501-EE40F5BE-1AF8-40A5-8BF7-29471B57B1BAQ37554396-C5781F50-8DE8-4D36-9D1E-A93C1067C765Q37681555-55507BD5-0CDE-46B4-8658-9C1C6AEF031AQ37714896-D7ACF81C-92EF-4C90-A64C-0FCBBD281DEBQ37942267-70856D0A-6F1D-4B5D-96E5-A62A882B8125Q37998107-00C09C95-A5C8-4876-97B3-2009A04158D2Q37998531-E03A2548-D1EF-47B8-9808-AF913E9C7339Q38010342-50618136-9F7A-4731-8797-FFC75B001935Q38080762-C7EA752F-F595-4A05-B5BB-36D694563487Q38081102-29FB4ECD-1612-4E76-94CB-7377AB0D6D18Q38181011-4873ED54-03B0-4E4D-A53A-8CCD08041B06Q38186650-F45FCCFF-491D-4302-86AB-A4CAB00EE298Q38236698-0439F88E-9DD2-49AB-A8B3-68BD42E7A4D1Q38267318-C11C5B06-AA4F-4289-8079-9F0A38EEA9A2Q38351399-FBB746BD-B14E-4FB3-96B4-5EF85E13BD09Q38570611-73496E51-F0E9-4803-A5C7-D913B61383C9
P2860
Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Considerations in the use of c ...... riers between blood and brain.
@ast
Considerations in the use of c ...... riers between blood and brain.
@en
type
label
Considerations in the use of c ...... riers between blood and brain.
@ast
Considerations in the use of c ...... riers between blood and brain.
@en
prefLabel
Considerations in the use of c ...... riers between blood and brain.
@ast
Considerations in the use of c ...... riers between blood and brain.
@en
P1476
Considerations in the use of c ...... rriers between blood and brain
@en
P2093
Meindert Danhof
P304
P356
10.2165/00003088-200241100-00001
P577
2002-01-01T00:00:00Z
P5875
P6179
1007005956